IVAX Diagnostics Reminds its Stockholders to Vote Today
June 06 2011 - 3:45PM
Business Wire
IVAX Diagnostics, Inc. (NYSE Amex: IVD) is reminding its
stockholders to vote their shares in anticipation of IVAX
Diagnostics’ 2011 Annual Meeting of Stockholders, which is
scheduled to be held on Friday, June 10, 2011.
Kevin Clark, IVAX Diagnostics’ President, Chief Executive
Officer and Chief Operating Officer, states to IVAX Diagnostics’
stockholders as of the close of business on April 15, 2011, the
record date for the Annual Meeting, “The Annual Meeting is only a
short time away. In order for your vote to be counted, please take
the time to cast your vote today. The voting process is simple. You
can vote via the Internet or telephone or by mail. If you have any
questions or need assistance voting your shares, please call
Georgeson Inc., which is IVAX Diagnostics’ proxy solicitor for the
Annual Meeting, toll-free at 1-866-297-1410.
“IVAX Diagnostics is asking that you vote 'FOR' all of the
proposals to be considered at the Annual Meeting, as recommended by
the Board of Directors of IVAX Diagnostics. If you do not vote your
shares of our common stock, then your failure to vote will have the
same effect as a vote cast 'AGAINST' three of the proposals to be
considered at the Annual Meeting, which are set forth in the Proxy
Statement that IVAX Diagnostics previously mailed to you and filed
with the Securities and Exchange Commission on April 18, 2011."
Mr. Clark concluded, “If IVAX Diagnostics does not receive the
required number of votes before the Annual Meeting as further
described in the Proxy Statement it had previously mailed and
filed, then IVAX Diagnostics may be required to curtail or reduce
its operations and IVAX Diagnostics may not be able to survive and
any investment in IVAX Diagnostics may be lost.”
About IVAX Diagnostics, Inc.
IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered
in Miami, Florida, is a fully integrated in vitro diagnostics
company that develops, manufactures and distributes in the United
States and internationally, proprietary diagnostic reagents, test
kits and instrumentation, primarily for autoimmune and infectious
diseases, through its three subsidiaries: Diamedix Corporation
(U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc.
(U.S.).
Safe Harbor Statement
Except for the historical matters contained herein, statements
in this press release are forward-looking and are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect the
business and prospects of IVAX Diagnostics, Inc., including,
without limitation, the risks and uncertainties associated with:
IVAX Diagnostics’ ability to solicit additional proxies in support
of the proposals to come before the Annual Meeting of Stockholders;
and other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements.
In addition to the risks and uncertainties set forth above,
investors should consider the economic, competitive, governmental,
technological and other risks and uncertainties discussed in IVAX
Diagnostics’ filings with the Securities and Exchange Commission,
including, without limitation, the risks and uncertainties
discussed under the heading “Risk Factors” in such filings.
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From May 2024 to Jun 2024
Ivax Diagnostics (AMEX:IVD)
Historical Stock Chart
From Jun 2023 to Jun 2024